Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...

Victory Capital Management Inc. decreased its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 1.9% during the 4th quarter, Holdings Channel reports. The firm owned 18,004 shares ...

Alnylam Pharmaceuticals, Inc.’s ALNY share price has surged by 11.75%, which has investors questioning if this is right time ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Metagenomi (MGX) to $20 from $25 and keeps an Overweight rating on the shares.

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) today and set a price ...